Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: March 23, 2023

Patent: 5,580,755

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 5,580,755
Title: Human pluripotent granulocyte colony-stimulating factor
Abstract:Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor (\"hpG-CSF\") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, e.g., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.
Inventor(s): Souza; Lawrence M. (Thousand Oaks, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Application Number:08/459,298
Patent Claims:see list of patent claims

Details for Patent 5,580,755

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 02/20/1991 See Plans and Pricing 2013-12-03
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 06/28/2000 See Plans and Pricing 2013-12-03
Amgen, Inc. NEULASTA pegfilgrastim Injection 125031 01/31/2002 See Plans and Pricing 2013-12-03
Amgen, Inc. NEULASTA ONPRO pegfilgrastim Injection 125031 12/23/2014 See Plans and Pricing 2013-12-03
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.